WO2003102584A3 - Semaphorin-like proteins and methods of using same - Google Patents

Semaphorin-like proteins and methods of using same Download PDF

Info

Publication number
WO2003102584A3
WO2003102584A3 PCT/US2003/017412 US0317412W WO03102584A3 WO 2003102584 A3 WO2003102584 A3 WO 2003102584A3 US 0317412 W US0317412 W US 0317412W WO 03102584 A3 WO03102584 A3 WO 03102584A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
semaphorin
methods
same
inhibit
Prior art date
Application number
PCT/US2003/017412
Other languages
French (fr)
Other versions
WO2003102584A2 (en
Inventor
Enrique Alvarez
David W Anderson
Mohanraj Dhanabal
Nikolai V Khramtsov
William J Larochelle
Henri S Lichenstein
Li Li
Chean Eng Ooi
Muralidhara Padigaru
Richard A Shimkets
Mei Zhong
Original Assignee
Curagen Corp
Enrique Alvarez
David W Anderson
Mohanraj Dhanabal
Nikolai V Khramtsov
William J Larochelle
Henri S Lichenstein
Li Li
Chean Eng Ooi
Muralidhara Padigaru
Richard A Shimkets
Mei Zhong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/403,676 external-priority patent/US20040029150A1/en
Application filed by Curagen Corp, Enrique Alvarez, David W Anderson, Mohanraj Dhanabal, Nikolai V Khramtsov, William J Larochelle, Henri S Lichenstein, Li Li, Chean Eng Ooi, Muralidhara Padigaru, Richard A Shimkets, Mei Zhong filed Critical Curagen Corp
Priority to CA002487939A priority Critical patent/CA2487939A1/en
Priority to JP2004509418A priority patent/JP2005528434A/en
Priority to AU2003245387A priority patent/AU2003245387A1/en
Priority to EP03739026A priority patent/EP1549951A4/en
Publication of WO2003102584A2 publication Critical patent/WO2003102584A2/en
Publication of WO2003102584A3 publication Critical patent/WO2003102584A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The proteins of the invention are a family used to modulate the activity of cells and their ability to attract blood vessels. The proteins are used to inhibit angiogenesis, inhibit cell migration, and inhibit actin filament formation. These proteins are used in this context to diagnose and treat proliferative disorders such as cancer.
PCT/US2003/017412 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of using same WO2003102584A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002487939A CA2487939A1 (en) 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of using same
JP2004509418A JP2005528434A (en) 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of use
AU2003245387A AU2003245387A1 (en) 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of using same
EP03739026A EP1549951A4 (en) 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of using same

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US38479802P 2002-05-30 2002-05-30
US60/384,798 2002-05-30
US40240702P 2002-08-09 2002-08-09
US60/402,407 2002-08-09
US44306203P 2003-01-28 2003-01-28
US60/443,062 2003-01-28
US10/403,676 2003-03-31
US10/403,676 US20040029150A1 (en) 1999-03-09 2003-03-31 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Publications (2)

Publication Number Publication Date
WO2003102584A2 WO2003102584A2 (en) 2003-12-11
WO2003102584A3 true WO2003102584A3 (en) 2004-02-19

Family

ID=29716299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017412 WO2003102584A2 (en) 2002-05-30 2003-05-30 Semaphorin-like proteins and methods of using same

Country Status (5)

Country Link
EP (1) EP1549951A4 (en)
JP (1) JP2005528434A (en)
AU (1) AU2003245387A1 (en)
CA (1) CA2487939A1 (en)
WO (1) WO2003102584A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227518A1 (en) * 2005-12-02 2009-09-10 The Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
EP2114433B1 (en) * 2007-02-02 2014-04-09 Biogen Idec MA Inc. Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031252A1 (en) * 1998-11-26 2000-06-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Human semaphorin 6a-1 (sema6a-a), a gene involved in neuronal development and regeneration mechanisms during apoptosis, and its use as a potential drug target
US6863889B2 (en) * 1999-03-09 2005-03-08 Curagen Corporation Polynucleotides and proteins encoded thereby
US6689866B1 (en) * 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
AU2003230775A1 (en) * 2002-04-01 2003-10-20 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 2 June 2000 (2000-06-02), BEHL ET AL.: "Human semaphorin 6A-1", XP002972634, Database accession no. (AAY71460) *
KLOSTERMANN ET AL.: "The orthologous human and murine semaphorin 6A-1 proteins (SEMA ^ A-1/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal Zyxin-like domain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 50, 15 December 2000 (2000-12-15), pages 39647 - 39653, XP002171338 *

Also Published As

Publication number Publication date
WO2003102584A2 (en) 2003-12-11
AU2003245387A1 (en) 2003-12-19
CA2487939A1 (en) 2003-12-11
EP1549951A2 (en) 2005-07-06
JP2005528434A (en) 2005-09-22
EP1549951A4 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2005000095A3 (en) Isoforms of brain natriuretic peptide
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003083041A8 (en) Cripto-specific antibodies
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003059942A3 (en) Peptides and peptidomimetics having anti-proliferative activity and their use
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2000066731A3 (en) Recombinant laminin 5
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
IL149416A0 (en) Human enzymes of the metalloprotease family
WO2003102584A3 (en) Semaphorin-like proteins and methods of using same
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2487939

Country of ref document: CA

Ref document number: 2003739026

Country of ref document: EP

Ref document number: 2004509418

Country of ref document: JP

Ref document number: 2003245387

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003739026

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003739026

Country of ref document: EP